Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer

por Ullenhag, Gustav J., Mozaffari, Fariba, Broberg, Mats, Mellstedt, Håkan, Liljefors, Maria
Publicado 2017

Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints

por Winqvist, Maria, Mozaffari, Fariba, Palma, Marzia, Eketorp Sylvan, Sandra, Hansson, Lotta, Mellstedt, Håkan, Österborg, Anders, Lundin, Jeanette
Publicado 2016

T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers

por Palma, Marzia, Gentilcore, Giusy, Heimersson, Kia, Mozaffari, Fariba, Näsman-Glaser, Barbro, Young, Emma, Rosenquist, Richard, Hansson, Lotta, Österborg, Anders, Mellstedt, Håkan
Publicado 2017

Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells

por Kokhaei, Parviz, Hojjat-Farsangi, Mohammad, Mozaffari, Fariba, Moshfegh, Ali, Pak, Fatemeh, Rashidy-Pour, Ali, Palma, Marzia, Hansson, Lotta, Österborg, Anders, Mellstedt, Håkan
Publicado 2018

Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia

por Hojjat-Farsangi, Mohammad, Jeddi-Tehrani, Mahmood, Daneshmanesh, Amir Hossein, Mozaffari, Fariba, Moshfegh, Ali, Hansson, Lotta, Razavi, Seyed Mohsen, Sharifian, Ramazan Ali, Rabbani, Hodjattallah, Österborg, Anders, Mellstedt, Håkan, Shokri, Fazel
Publicado 2015